Arvinas, Inc.

Healthcare

NASDAQ:ARVN · NASDAQ Global Select

Market Cap $457.46M Beta 1.75 P/E (TTM) -2.2

$7.58 +6.91%

+$0.49 today

52W Low $6.06High $14.51

Vol 0.86M · Avg 0.89M

EPS (TTM)-$3.46

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+2.57%

Period High

$13.83

Period Low

$6.24

Latest

$7.58

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Erasca, Inc.

NASDAQ:ERAS

$4.37B

Day One Biopharmaceuticals, Inc.

DAWN

$2.22B

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

$1.46B

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

$1.42B

MeiraGTx Holdings plc

NASDAQ:MGTX

$888.13M

Geron Corporation

NASDAQ:GERN

$737.75M

Replimune Group, Inc.

NASDAQ:REPL

$733.24M

Astria Therapeutics, Inc.

ATXS

$718.13M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

$515.41M

Valneva SE

NASDAQ:VALN

$507.78M

What is the latest ARVN filing?

The latest filing shown is 8-K dated Jun 2, 2026.

How many recent filings does ARVN have?

Intrinsic Alpha currently shows 20 recent filings for ARVN.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.